There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Danaher (DHR – Research Report) and Sanofi-Aventis Sa (SNY – Research Report) with bullish sentiments.
Danaher (DHR)
In a report released yesterday, Michael Ryskin from Bank of America Securities maintained a Buy rating on Danaher, with a price target of $310.00. The company’s shares closed last Friday at $269.85.
According to TipRanks.com, Ryskin is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Danaher with a $301.46 average price target, a 12.2% upside from current levels. In a report issued on January 22, RBC Capital also maintained a Buy rating on the stock with a $293.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Sanofi-Aventis Sa (SNY)
Bank of America Securities analyst Graham Parry reiterated a Buy rating on Sanofi-Aventis Sa today and set a price target of $65.00. The company’s shares closed last Friday at $46.02.
Parry has an average return of
According to TipRanks.com, Parry is ranked #3715 out of 8328 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sanofi-Aventis Sa with a $65.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DHR:
- Danaher has expressed takeover interest in Catalent, Bloomberg says
- Danaher price target lowered to $320 from $340 at Cowen
- Danaher price target lowered to $309 from $321 at Baird
- Danaher Corporation Reports Earnings: Did it Beat Estimate Forecasts?
- Danaher price target raised to $321 from $315 at Baird
